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Historically, in the 1950s, the chemist Linus Pauling established a relationship between decreased longevity and
obesity. At this time, with the advent of studies involving the mechanisms that modulate appetite control, some
researchers observed that the hypothalamus is the “appetite centre” and that peripheral tissues have important
roles in the modulation of gut inflammatory processes and levels of hormones that control food intake. Likewise,
the advances of physiological and molecular mechanisms for patients with obesity, type 2 diabetes mellitus,
inflammatory bowel diseases, bariatric surgery and anorexia-associated diseases has been greatly appreciated by
nutritionists. Therefore, this review highlights the relationship between the gut-central nervous system axis and
targets for nutritional therapies.
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Introduction
The energy balance is determined by the relationship
between the acquisition and expenditure of energy. This
perfect interaction occurs among physiological signals in
peripheral organs and the central nervous system (CNS).
Apart from the obvious digestive and absorptive func-
tions of the gastrointestinal tract, gut and adipose tissue
hormones play an important role in controlling the
energy balance, particularly via the regulation of food
intake in both the short- and long-term, respectively.
Therefore, the enteric nervous system (ENS), gut hor-
mones, and nutrients act in the control process at the
beginning and termination of meals [1,2].
The CNS-gut axis is controlled by the ENS and its
importance in the health and disease has been recog-
nised by several studies [3,4]. According to health pro-
fessionals, advances in the physiological and molecular
mechanisms involving the ENS are responsible for the
control of the energy balance, and for the nutritional
therapies used in patients with obesity, type 2 diabetes
mellitus, inflammatory bowel diseases (IBDs), bariatric
surgery and cancer-associated anorexia [5-9].
In the 1950s, the chemist Linus Pauling established a
relationship between decreased longevity and obesity
[10]. At this time, with the advent of studies involving
the mechanisms that modulate appetite control, it was
recognised that the hypothalamus is the “appetite cen-
tre”. In rats, some researchers observed that lesions in
the lateral hypothalamus produced anorexia (hunger
centre) and lesions in the ventromedial nuclei of the
hypothalamus produced obesity (satiety centre) [11-14].
More recently, the discovery of cloned leptin in 1994,
which is produced and secreted by adipose tissue, pro-
vided some evidence that appetite control could also be
modulated by peripheral tissues [15].
In relation to the mechanisms of intestinal hormonal
action, the beginning of the food intake process results
in the release of anorexigenic hormones, such as peptide
YY (PYY), the glucagon-like peptide 1 (GLP-1), oxynto-
modulin (OXM), the glucose-dependent insulinotropic
polypeptide (GIP), cholecystokinin (CCK) and prouro-
guanylin (Figure 1). Likewise, the CNS receives and inte-
grates several factors, adjusting the energy balance in
accordance with energetic necessity. Overall, the secre-
tion of anorexigenic hormones (including PYY, GLP-1,
OXM, GIP, CCK and prouroguanylin) and the activation
of neuropeptides, such as POMC and CART, occurs in
the postprandial state. On the other hand, the greater
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vation of the neuropeptides AgRP and NPY occurs in
the fasting state [16-18] (Figure 1). In the next step, the
main gut hormones that influence energy homeostasis
are summarised (Table 1).
For nutrition professionals, the gut-CNS axis is con-
sidered an attractive opportunity, because foods may
help to treat and prevent diseases. In this review, we dis-
cuss the fact that nutritional therapies could modify the
gut flora and may reach the CNS in order to modulate
the food intake and inflammatory processes. Some
nutritional therapies that are known to modulate the
gut-CNS axis via physiological and molecular mechan-
isms are also discussed.
The main underlying mechanisms behind the connection
between microbiota and the central nervous system
The components that interact to form this complex
brain-gut communication is bidirectional, with stimuli
from gastrointestinal tract (GIT) that influences the
brain functions and messages from the brain that may
alter some GIT activities, such as motor, sensory and
secretory [19]. It was demonstrated that this link occurs
via the vagus nerve to the brainstem, and via spinal
afferents to the spinal cord [20]. Recently, Bravo et al.
[21] showed that vagotomized mice did not exhibit
behavioral and neurochemical effects that L.rhamnosus
exerts in CNS, evidencing the correlation of the vagus
nerve in the direct communication between the bacteria
and the brain.
Moreover, the serotonin (5-HT) levels and hypothala-
mic-pituitary-adrenal (HPA) axis may also participate in
this connection. All connections are involved with mod-
ulation of infections and inflammatory diseases, such as
obesity, type 2 diabetes mellitus, ulcerative colitis,
Crohn’s disease, as well as with behavioural problems
and psychiatric disorders, such as cognition, mood,
emotion, stress and anxiety [21,22].
Diets and microbiota: A general overview
The microbes that reside in the gut favors the harvest of
energy from food, influence the metabolic profiling of
organs and exerts nutritional and protective effects on
the intestinal epithelium and immune system [23-25].
Figure 1 Role of gut hormones in fasting (right) and
postprandial (left) state. During fasting, occurs greater release of
ghrelin from the stomach that acts in arcuate nucleus via vagus
nerve stimulating hunger. During the fed state (postprandial), occurs
release of anorexigenic hormones (GLP-1, OXM, PYY, CCK and GIP)
that reach the arcuate nucleus via the brainstem and vagus nerve,
activating the satiety. GLP-1: glucagon-like peptide 1, OXM:
oxyntomodulin, PYY: peptide YY, CCK: cholecystokinin, GIP: glucose-
dependent insulinotropic polypeptide.
Table 1 Summary of the main gut hormones that influence the energy homeostasis
Gut hormones (receptor) Secretion site Action
PYY (G protein-coupled receptors) L cells of gut ↓ food intake and delays gastric emptying
GLP-1 (GLP-1R) L cells of gut ↓ food intake, releases insulin, hand out as incretin, ↓ glucose levels and delays gastric
emptying
OXM (GLP-1R) L cells of gut ↓ food intake








GIP K cells of gut ↓ food intake and glucose levels
PP (Y4 and Y5) PP cells of pancreas ↓ food intake
Amylin (AMY 1-3) b cells of pancreas ↓ glucose levels
Insulin (IR) b cells of pancreas ↓ food intake and glucose levels
Glucagon (GCGR) a cells of pancreas ↑ glucose levels and insulin secretion
Ghrelin (GHSR1) Stomach ↑ food intake
PYY: peptide tyrosine tyrosine; GLP-1: glucagon-like peptide 1; PP: pancreatic polypeptide; OXM: oxyntomodulin; CCK: cholecystokinin; GHSR1: growth hormone
secretagogue; GUCY2C receptors: guanylyl cyclase 2 C receptors; IR: insulin receptor; GIP: glucose-dependent insulinotropic peptide.
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that are divided in two main phylotypes: Bacteroidetes
and Firmicutes [26,27].
Supporting normal digestion and host metabolism, gut
microbiota is able to expand nutrient availability, releas-
ing energy through fermentation of otherwise non-diges-
tible oligosaccharides or by modulating absorption. The
short chain fatty acids (SCFA), which are the major
metabolic products of anaerobic bacteria fermentation,
are an important energy source for humans, being used
by colonocytes, liver and muscle. It has been reported
that 5 to 10% of human basal energy requirements are
provided by SCFA [28-31].
Since the interactions of microbes with host leads to a
complex balance of host genes, alteration of microbiota
population can cause several metabolic disorders.
R e c e n t l y ,C r y a n&O ’Mahony [19] suggested that
numerous conditions may modify the microbiota, such
as obesity, IBDs, antibiotics, infections and diets [22,32].
Therefore, the roles of the gut-CNS axis on metabolic
diseases, focusing on the physiological and nutritional
aspects are summarised in the Figure 2.
Obesity and type 2 diabetes mellitus
Since it is known that the microbiota is related to
energy homeostasis, digestion of nutrients and metabo-
lism, some low-grade inflammation-related diseases have
emerged as an attractive opportunity for researchers.
The first studies to observe that obese microbiota have
an enhanced ability to absorb energy from the diet were
described by Jeffrey Gordon’s group [33,34].
Cani et al. [35] proposed that both obesity and type 2
diabetes mellitus can be characterised by increased lipo-
polysaccharide (LPS) levels. For instance, in the presence
of diet induced obesity (DIO), the LPS concentrations
are higher than in the fasting state. In addition, either
DIO animals or those submitted to subcutaneous injec-
tions of LPS represent enhanced LPS-containing micro-
biota, as well as glucose and body weight gain. Likewise,
these authors were the first to demonstrate that “meta-
bolic endotoxaemia” initiates obesity [35].
Recently, it has been shown that food rich in saturated
or trans-fatty acids stimulates inflammatory markers
[9,36-40]. Raybould [41] suggests that intestinal inflam-
mation is associated with obesity due to high LPS levels.
In 2011, it was shown that the ingestion of trans fatty
acids during gestation and lactation led to an increase in
blood LPS levels, the activation of inflammatory signal-
ling in the hypothalamus and an increased food intake
in adult offspring rats [9]. Moreover, the same studies
[27,42] observed the presence of intestinal inflammation
in different models of obesity, such as eating a high-fat
diet, rich in saturated fatty acids and genetic obesity.
When evaluating inflammatory markers in CONV
mice fed with a high-fat diet, Ding et al. [43] observed
increased body weights and activation of gut TNF-a
mRNA expression. Likewise, Caricilli et al. [27] showed
increased blood LPS levels in toll-like receptor 2
(TLR2)-deficient mice when compared to wild-type
mice. TLR2 deficient mice showed activated phosphory-
lation of janus kinase (JNK), TLR4 and phosphorylation
in serine of the insulin receptor substrate-1 of several
tissues [27]. In this work, the authors suggest that an
increase in LPS levels together with TLR4, in the
absence of changes of TLR2, result in a compensatory
action that may lead to increased activation of TLR4.
Together, this would contribute to insulin resistance in
TLR2-deficient mice [27]. Likewise, in a previous study
[9] performed with adult offspring rats from mothers
fed trans fatty acids during gestation and lactation,
increased blood LPS levels and hypothalamic TLR4
expression were seen with no change to hypothalamic
TLR2 expression. Moreover, the increase of blood LPS
provoked by a high-fat diet has also been shown by
other recent studies [44,45]. It has also been shown that
the actions of fatty acids are aggravated by physiological
ligands of G-protein-coupled receptors, such as GPR40,
41, 43, 84 and 119, and, therefore, it may be involved in
the progression of several inflammatory diseases [46].
Another TLR described to influence microbiota is
TLR5. Vijay-Kumar et al. [47] demonstrated that mice
deficient in TLR5 exhibit obesity, hyperphagia, dyslipi-
daemia, hypertension and insulin resistance, and that
they also show an altered composition of gut
Figure 2 Role of gut-central nervous system axis on
inflammatory diseases.
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lower Bacteroidetes (39.8%).
In addition to inflammatory processes, non-alcoholic
fatty liver disease (NAFLD) is a typical hepatic manifes-
tation that has been found to be obesity-related.
Recently, inflammasome-deficient mice were shown to
have modifications of gut microbes population through
the influx of TLR4 and TLR9 agonists into the portal
circulation. Therefore, increased hepatic inflammation
levels can lead to the development of NAFLD and obe-
sity [48].
An important study that demonstrated the relation-
ship between intestinal bacterial and obesity in humans
was published by Wu et al. in 2011 [49]. In this study, it
was found that an increased fat intake and low dietary
fibre are associated with the modulation of intestinal
microbiota. The authors of this study showed that ani-
mal proteins and saturated fatty acids are associated
with increased Bacteroidetes levels, and that diets con-
taining carbohydrates but lacking meat and dairy pro-
ducts increased Prevotella levels. Together, these facts
create a profile of weight gain and gut inflammation-
related bacteria.
DIO experimental models also indicate low expression
of tight junction proteins in the gut, and the increasing
in intestinal permeability [41]. Brun et al. [50] found in
either ob/ob and db/db mice, an alteration in the intest-
inal permeability same when mice were submitted to
standard chow consumption. In rats fed with hyper-lipi-
dic diet also was observed an increase of intestinal per-
meability through the reduction of tight junction
proteins, such as claudin 1, claudin 3 and junctional
adhesion molecule-1 [51].
Collectively, several obesity models have observed that
a major determinant of intestinal permeability is the
intercellular tight junction proteins. Tight junctions are
organised by the same transmembrane proteins, such as
occludin, claudin and junctional adhesion molecule-1
[52-54]. Therefore, these transmembrane proteins inter-
act with Zonula Occludens (ZO-1-3), which anchors the
transmembrane proteins [55] provoking an increase of
intestinal permeability. The increased intestinal perme-
ability is thought to be associated with a higher activity of
pathogenic bacteria and inflammatory processes. In sum-
mary, some studies have described that the main tight
junction proteins responsible for this intestinal perme-
ability are ZO-1, myosin light chain, occludin, claudin
and junctional adhesion molecule 1 [44,50,52-54,56,57].
Several papers suggest that saturated fatty acids might
enhance the blood LPS levels through GPRs, possibly
secreted by gut cells, may affect the CNS and alter
numerous central inflammatory markers. In addition,
the increased intestinal permeability aggravated by a
high-fat diet and LPS may also be responsible for altered
epithelial barrier function, and it is therefore possible
that the high prevalence of obesity and type 2 diabetes
mellitus is connected with an altered gut microbiota-
CNS axis.
Bariatric surgery
In the middle of the 1950s, Kremen et al. [58] postu-
lated that bypass surgery in dogs reduced food absorp-
tion. Recently, in humans, bariatric surgery has been
found to be a procedure which results in patients
rapidly losing weight, accompanied by the resolution of
type 2 diabetes mellitus and a reduction of cardiovascu-
lar deaths [45,59]. However, the mechanisms underlying
the improvement of metabolic parameters have not
been fully elucidated. Likewise, Evans et al. [60] have
shown that obese patients had an increase of blood PYY
levels and GLP-1 was restored to normality after gastric
bypass surgery compared top a t i e n t sw i t hn o r m a l
weights. Short-term Rouxen-Y gastric bypass (six
months) was able to activate PYY and GLP-1 secretion,
and stimulated the satiety in response to a liquid-meal
intake in normal, glucose-tolerant obese patients [61].
Falkén et al. [62] reported that patients had a progres-
sive rise of the GLP-1 and OXM concentrations after
gastric bypass and that this procedure favours weight
loss and improved insulin sensitivity.
Collectively, the published data has shown that, after
bariatric surgery, numerous gut hormones can reduce
the appetite and normalise glucose homeostasis, and
that the main actions are modulated through GLP-1,
PYY, OXM, ghrelin, insulin and leptin [63]. Moreover,
an increased secretion of anorexigenic hormones, such
as GLP-1 and PYY occurs with bariatric surgery (Figure
3). It is also possible to speculate that the bariatric sur-
gery might modulate the intestinal permeability and
enhancement of anorexigenic gut hormone secretion,
alongside the reduction of inflammation seen in obese
Figure 3 Secretion sities of anorexigenic hormones, such as
glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) are
increased after bariatric surgery.
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is known that theses anorexigenic hormones might acti-
vate POMC and CART neuropeptides in order to
reduce the food intake and body weight, and also help
to moderate energy expenditure.
Inflammatory bowel diseases (IBDs)
The IBDs, that affect the health of humans, include
ulcerative colitis, Crohn’s disease and irritable bowel
syndrome (IBS) [64-66]. Macfarlane et al. [67] have sug-
gested that the appearance of these diseases may be due
to modified gut microbiota, or as a consequence of local
inflammation. However, a recent study has shown that
the intestinal wall of either inflamed or non-inflamed
guts [68] may be associated with severe disease. Like-
wise, human studies of patients diagnosed with IBDs
have observed increased TLR2, TLR4 and TLR5 expres-
sion in the gut wall [69,70], and other studies have
reported an increase of the IL-6, IL-8, TNF-a and inter-
feron-gamma levels [71-73]. Therefore, it is possible to
observe that in IBDs that have an inflammatory status
higher than that of obesity, more severe disease symp-
toms are seen. In order to investigate the effects of
neuro-inflammation in animals submitted to experimen-
tal IBD, Wang K, et al. [74] observed increased IL-6
mRNA expression in both the colon and brain of these
animals when compared to control animals.
Collectively, it can be speculated that higher levels of
gut-related inflammation lead to a reduction of food
intake and malnutrition due to the activation of cyto-
kines in the CNS. According to Pavlov & Tracey [75],
the autonomic nervous system plays a key role in the
control of the brain in moderating the immune system
and inflammation.
In summary, several studies have reported that inflam-
matory bowel problems are linked to a reduction of Lac-
tobacillus spp and Bacteroidetes, and an increase of the
Firmicutes-Bacteroidetes ratio [76-79]. These changes in
intestinal flora are aggravated through alterations in the
immune system that underlie disease pathogenesis.
Nutritional therapies that improve metabolic diseases
through the gut-CNS axis
While microbes have been used to study the underlying
mechanisms of inflammatory diseases and insulin resis-
tance, numerous researchers have also stated that nutri-
tional components could be used as a strategy to
combat the gravity of these abnormalities. Historically,
the Greek physician Hippocrates, “The father of medi-
cine”, reportedly said “Let your food be your medicine,
and your medicine be your food”.
Among the nutritional components that support a
healthy intestinal microbiota, we highlight the dietary
fibres, probiotics and prebiotics [80-84]. The
improvements include a reduction of systemic and local
inflammation, as well as less intestinal pain and discom-
fort, when both probiotics and prebiotics are used
[80,85,86]. In addition, other studies have shown an
inhibition of bacterial translocation and a reduction of
intestinal permeability with the use of these nutrients
[87,88].
One study demonstrated that the use of oligofructose,
a prebiotic, enhanced the levels of Bifidobacterium spp.,
and improved insulin sensitivity, as well as restoring
inflammatory status through decreased endotoxaemia
metabolism [80].
Oligofructose and resistant starches have been demon-
strated to increase short-chain fatty acid-induced GLP-1
expression [89], and to reduce ghrelin expression [90].
Moreover, in a recent review the nutrients and diets
that stimulate the anorexigenic gut peptides, reduce the
food intake and break off the obesity were summarised.
The main nutrients and diets that can increase the
GLP-1, CCK, GIP, OXM and PYY secretion are dietary
fibre, dairy products, unsaturated fatty acids and a nor-
mal calorie diet [2].
Recently, it was observed that a prebiotic-enriched diet
reduced Firmicutes and increased Bacteroidetes levels, as
well as improving glucose sensitivity, body fat, inflam-
mation and oxidative stress [91]. Furthermore, a recent
review suggested that SCFA providers provided of diet-
ary fibers, such as propionate and butyrate, induce the
reduction of food intake by increasing leptin secretion
and reducing pro-inflammatory cytokine expression
[92]. These dietary fibres are fermented by microbiota,
and higher butyric acid levels were found in animals fed
with diets containing a mixture of oligofructose and raf-
finose [93].
Necrotising pancreatitis patients with diarrhoea
received semi-elemental nutrients via jejunal feeding,
and an increase in faecal short-chain fatty acids, such as
acetate, propionate and butyrate were found when com-
pared to pre-treatment levels. In addition, a resolution
of diarrhoea episodes was seen in approximately 66% of
patients. Therefore, this study suggests that dietary fibre
supplementation is an excellent method for the
improvement of healthy intestinal microbiota, and
results in reduced symptoms of dysbiosis [81].
Concomitant to numerous “healthy” nutrients, it is
possible that unsaturated fatty acids, such as omega-3,
are an attractive option for the improvement of inflam-
matory processes, and that this can be modulated by the
physiological ligand of these fatty acids, GPR120 [94,95].
In relation to high-grade inflammatory diseases, such
as a provoked by Human Immunodeficiency Virus type1
(HIV-1), patients were shown to have infections in lym-
phoid tissue, alterations of intestinal microbiota and
impaired symptoms of Acquired Immunodeficiency
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is suggested for the prevention of progression of HIV-
linked infections [96].
It has been recognised that obese, insulin-resistant and
IBD subjects represent a group requiring moderation of
intestinal microbiota due to a higher risk of the develop-
ment of cancer. This is because the mechanisms by
which intestinal bacteria induce carcinogenesis are
thought to be via chronic inflammation, immune system
evasion and immunosuppression. Conversely, the pro-
biotics used have also emerged as an possible mechan-
ism for the reduction of the pro-inflammatory status
seen in cancer patients [97].
Collectively, this topic has summarised the main phy-
siological and metabolic alterations that modify illnesses
of the gut both before and after nutritional therapy (Fig-
ure 4).
Although nutritional compounds are important for the
improvement of health, changes to diets, such as an
increase of either fruit or vegetable consumption, as well
as a reduction of refined carbohydrates and saturated
and trans-fatty acids [98,99], are required, as food
restriction can prevent obesity in humans [98,99] and
mice deficient in the TLR5 [47]. Furthermore, micronu-
trients and macronutrients from existing diets are tar-
gets for gut health and strengthening of the immune
system [100].
The studies discussed in this review collectively sup-
port the emerging view that microbiota contribute to
metabolic disease, and suggest that an impaired diet
quality may promote the development of inflammatory
diseases. However, some nutrients that have been stu-
died, such as dietary fibres, and probiotic and prebiotic
nutrients, along with bariatric surgery, are one possible
option for the maintenance of intestinal health, and the
improvement of the gut-CNS axis (Figure 5).
In summary, the discoveries in understanding these
foods and nutrients could help to regulate the gut-CNS
axis, but remain a challenge for nutritionists and
scientific investigators. Therefore, future research must
be focused on looking to improve the effectiveness of
diets for the prevention of inflammation between the
gut-CNS axis, as well as for the maintenance of micro-
bial homeostasis of the gut.
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